nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.09.2019 | Letter to the Editor

Comment on: “the FDG PET/CT score” for the diagnosis of malignant pleural effusion

verfasst von: Dharmender Malik

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346:1971–7. https://doi.org/10.1056/NEJMcp010731.CrossRefPubMed

Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. BTS pleural disease guideline group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii32–40. https://doi.org/10.1136/thx.2010.136994.CrossRefPubMed

Nakajima R, Abe K, Sakai S. Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore). 2015 Jul;94(29):e1010. https://doi.org/10.1097/MD.0000000000001010.CrossRef

Sun Y, Yu H, Ma J, Lu P. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764. https://doi.org/10.1371/journal.pone.0161764.eCollection2016.CrossRefPubMedPubMedCentral

Porcel JM, Hernandez P, Martinez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147:502–12. https://doi.org/10.1378/chest.14-0820.CrossRefPubMed

Yang M-F, Tong Z-H, Wang Z, Zhang Y-Z, Xu L-L, Wang X-J, et al. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion. Eur J Nucl Med Mol Imaging. 2019;46(7):1457–67.CrossRef

Titel: Comment on: “the FDG PET/CT score” for the diagnosis of malignant pleural effusion
verfasst von: Dharmender Malik
Publikationsdatum: 04.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04512-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations

Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements

18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab

Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade